Conclusion
Based on our results, we conclude that there are significant differences in the use of VV-ECMO in treating ARDS due to COVID-19 to treating ARDS due to influenza. COVID-19 patients appear to be at a higher risk of bacterial superinfection, and prevention and control of bacterial infections may be critical in improving survival. More research is needed to understand the efficacy and risks of using ECMO to treat cases of COVID-19.
Table 1 : Contraindications for ECMO in COVID-19